Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2019-07-15 Regulatory Filings
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Eurobio Scientific: Bilan Semestriel du Contrat de Liquidite
Regulatory Filings Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC LOUIS CAPITAL MARKETS" (Semi-annual balance sheet of the liquidity contract...). It details the status of a liquidity contract (share count and cash balance) as of June 30, 2019, and transaction volumes for the first half of 2019. This type of report concerns the management of the company's own shares or market stabilization activities, which falls under the category of 'Transaction in Own Shares' (POS) or potentially a specific regulatory filing. Since the core content is about the activity related to the company's shares being managed under a specific agreement (liquidity contract), POS is the most appropriate fit, as it covers share repurchase/issuance activities, which liquidity contracts often facilitate or report on. It is not a standard financial report (10-K, IR) or an earnings release (ER). Given the specific nature of reporting on share transactions/management, POS is selected over the general RNS.
2019-07-15 French
Eurobio Scientific : compte-rendu de l’assemblée générale ordinaire et extraordinaire annuelle
AGM Information Classification · 99% confidence The document is titled "Compte-rendu de l'assemblée générale ordinaire et extraordinaire annuelle d'Eurobio Scientific" (Minutes of the Annual Ordinary and Extraordinary General Meeting of Eurobio Scientific). It explicitly details the resolutions adopted by shareholders during the meeting held on June 27, 2019, including the approval of a capital contribution (apport en nature) and the adoption of a new governance structure (board of directors). This content directly corresponds to the materials presented and voted upon at an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2019-06-28 French
Eurobio Scientific et Vivo Medical Group entrent en négociation exclusive pour l’acquisition de deux sociétés au Royaume-Uni (addendum)
M&A Activity Classification · 99% confidence The document is a press release dated June 12, 2019, announcing that Eurobio Scientific has entered into exclusive negotiations to acquire two UK companies (Pathway Diagnostics Ltd and Personal Diagnostics Ltd). It details the strategic rationale, the consideration (cash and stock exchange), and mentions that the resolutions for the stock issuance related to this acquisition will be submitted to shareholders at the Annual General Meeting (AGM) on June 27, 2019. This content describes a significant corporate transaction (M&A activity) and financing structure change, which falls under Capital/Financing Update (CAP) or M&A Activity (TAR). Since the core subject is the proposed acquisition and the terms of the deal, TAR (Merger/Takeover Activity) is the most specific fit. It is not a formal regulatory filing like a 10-K or an ER, but rather a corporate announcement about a transaction.
2019-06-12 French
Eurobio Scientific and Vivo Medical Group enter into exclusive negotiations for the acquisition of two companies in the United Kingdom (addendum)
M&A Activity Classification · 99% confidence The document announces that Eurobio Scientific has entered into exclusive negotiations to acquire two UK companies (Pathway Diagnostics Ltd and Personal Diagnostics Ltd) from Vivo Medical Group. The text details the nature of the target companies, the strategic fit, and the proposed payment structure, which includes a cash component and an exchange of shares. Crucially, it mentions that resolutions for the issuance of new shares related to this acquisition will be submitted for shareholder approval at the upcoming Annual General Shareholders' Meeting (AGM) on June 27, 2019, and that the meeting notice will appear in the BALO on June 12, 2019. Since the document is an announcement detailing a significant corporate action (M&A) that requires shareholder approval and mentions the upcoming AGM and the associated resolutions, it strongly relates to corporate governance and potential shareholder voting matters. However, the primary focus is the M&A activity itself. Given the options, 'M&A Activity' (TAR) is the most direct fit for the core subject matter (acquisition proposal). It is not a formal regulatory filing like a 10-K, an earnings release, or a simple dividend notice. It is a specific announcement about a takeover/merger proposal.
2019-06-12 English
Eurobio Scientific and Vivo Medical Group enter into exclusive negotiations for the acquisition of two companies in the United Kingdom
M&A Activity Classification · 99% confidence The document announces that Eurobio Scientific has entered into exclusive negotiations to acquire two UK companies (Pathway Diagnostics Ltd and Personal Diagnostics Ltd). It details the strategic rationale, the structure of the payment (cash and share exchange), and mentions that resolutions for the share issuance will be submitted for shareholder approval at the upcoming General Meeting on June 27, 2019. The text is a press release or corporate announcement detailing a significant business transaction (M&A activity). This fits the definition of M&A Activity (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement (PSI), but a specific announcement about a takeover/merger proposal.
2019-06-11 English
Eurobio Scientific et Vivo Medical Group entrent en négociation exclusive pour l’acquisition de deux sociétés au Royaume-Uni
M&A Activity Classification · 99% confidence The document announces that Eurobio Scientific is entering exclusive negotiations to acquire two UK companies (Pathway Diagnostics Ltd and Personal Diagnostics Ltd). It details the strategic rationale, the consideration (cash and share exchange), and crucially, mentions that the resolutions for the share issuance related to this acquisition will be submitted to shareholders at the Annual General Meeting (AGM) on June 27, 2019. The text also explicitly mentions the upcoming AGM date and that the related notice will appear in the BALO on June 12, 2019. Since the core content is a corporate action announcement (M&A) that directly relates to a future shareholder vote and mentions the AGM, it is most accurately classified as a general corporate announcement related to financing/capital structure changes or a significant event announcement. Given the context of M&A activity (TAR) and the mention of a future shareholder vote/AGM, the most fitting category is M&A Activity (TAR) as the primary driver, or potentially Capital/Financing Update (CAP) due to the share exchange component. However, the document is a press release detailing a transaction, not a formal regulatory filing like a 10-K or a specific proxy statement. Since it details a major transaction (acquisition), TAR is appropriate. If it were purely about the AGM mechanics, AGM-R would fit, but the M&A is the subject. Given the options, TAR (M&A Activity) is the best fit for a press release announcing an acquisition negotiation.
2019-06-11 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.